Reviva Pharmaceuticals (RVPH) Lytham Partners Fall 2026 Investor Conference summary

Company overview and lead product focus

• Focuses on developing novel therapies for CNS and metabolic indications, with brilaroxazine as the lead product in late-stage development for schizophrenia.

• Brilaroxazine is being evaluated for expansion into bipolar disorder, major depressive disorder, ADHD, and inflammatory conditions.

Clinical trial results and efficacy

• Phase III global trial for schizophrenia showed significant improvement in primary and secondary endpoints, with a 10-point separation from placebo in four weeks.

• Sustained, dose-dependent efficacy was observed over one year, with 46–50 point improvement from baseline and low relapse rates.

• Over 300 patients completed six months and 159 completed one year, exceeding regulatory requirements.

Safety and differentiation

• Discontinuation rates were 50% lower than other approved antipsychotics, with minimal motor, metabolic, endocrine, and cardiac side effects.

• No significant weight gain, hormonal dysfunction, or GI/liver adverse events were observed.

• Brilaroxazine demonstrated a cleaner safety profile and fewer sexual side effects compared to market leaders.